The frequently used Pap test has good specificity but relatively poor sensitivity…More

Bar graph icon TruScreen icon
Close

Cervical cancer is the second largest cause of cancer mortality in women…More

Bar graph icon TruScreen icon
Close

Direct medical costs associated with cervical cancer are estimated at US$300–400m/pa in the USA…More

Bar graph icon TruScreen icon
Close

TruScreen has proven to be more acceptable to women than a Pap test…More

Bar graph icon TruScreen icon
Close

Investing in TruScreen means a direct contribution to the health of women worldwide…More

Bar graph icon TruScreen icon
Close

Invasive cancer is most common in women over 45 but signs can appear much earlier…More

Bar graph icon TruScreen icon
Close

TruScreen offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and wellbeing of women around the world.

Truscreen Unit

Millions of women worldwide are unable to access cervical cancer screening.

Millions of women worldwide are unable to access cervical cancer screening.

Current pap smear testing is not effective in low-resource or developing health economies due to the lack of infrastructure and the highly trained personnel required to read the smear, as well as delays in reporting results, particularly in remote locations. More than 270,000 women die from this disease each year.

Learn more

Cervical cancer is a major cause of morbidity and mortality worldwide.

Cervical cancer is a major cause of morbidity and mortality worldwide.

It is the second largest cause of deaths due to cancer in women. The death toll is greatest in populations that lack cervical cancer screening programmes. Worldwide, there are approximately 500,000 new cases of cervical cancer diagnosed and more than 270,000 die from this disease each year.

Learn more

TruScreen has been clinically tested by over 10,000 women around the world.

TruScreen has been clinically tested by over 10,000 women around the world.

Studies have involved women from Australia, Brazil, Italy, Philippines, People’s Republic of China, Russia, Singapore, South Africa, Spain, United Kingdom and the United States of America. More than 17 clinical trials involving 10,000 women have been completed worldwide.

Learn more

Better access to cervical cancer screening will save thousands of lives.

Better access to cervical cancer screening will save thousands of lives.

Cervical cancer develops from slowly progressing intraepithelial lesions. If early changes in cervical cells are detected through screening programmes, cervical cancer is curable. However, if undetected until late in its clinical course, it has a high death rate.

Learn more

TruScreen supports cervical screening in remote areas and developing countries.

TruScreen supports cervical screening in remote areas and developing countries.

For many women in remote areas and developing countries, poor access to cervical screening in clinics means many women go undetected until it is too late. TruScreen provides mobile units which are easy to use and do not require lab facilities in order to diagnose women.

Learn more

TruScreen performs equal to, or better than, alternative cervical screening tools.

TruScreen performs equal to, or better than, alternative cervical screening tools.

The performance of TruScreen® has been tested in 17 clinical trials involving 10,000 women worldwide and was consistent and equal to, or better than in some studies, the comparing high quality cytology tests within the same study.

Learn more

TruScreen’s world-class technology has the power to save lives

TruScreen® is a cost-effective test that can be used outside existing laboratory infrastructure and has high potential to aid in reducing cervical cancer mortality. This new technology detects pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The system uses low levels of electricity and light to examine the cervix as a hand-held wand is gently moved over the surface of the cervix.

Unlike the Pap test, tissue samples are not collected, which minimises discomfort for patients. TruScreen® has been extensively evaluated in studies involving more than 10,000 women worldwide, and it has been proven as, or more, effective than top quality conventional Pap tests.

Learn More

Doctor
Back to top